



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : Shop No. 270, Shastri Market, Indore, Madhyapradesh. Phone : +91 98846 24100

To
The Deputy Gen. Manager,
Dept.of Corporate Services,
BSE Ltd,
P.J.Tower, Dalal Street,
Mumbai-400 001

06 March 2024

Sub: Revised Outcome of Board Meeting – Unaudited Financial Results for the Quarter and Nine Months ended 31 December 2014.

Dear Sir,

In Compliance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we are pleased to enclose the revised Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2014 with Limited Review which have been duly approved

We request you to kindly take above on record and do the needful at the earliest.

For Kabra Drugs Limited



Director
DIN: 02040505

KABRA DRUGS LIMITED

Regd. Office: 26, Sector A, Sanwer Road, Industrial Area, Indore. MP – 452 003

Unaudited Financial Results for the Quarter ended 31st December 2014

(Rs. In Lacs)

Part I		Quarter ended			9 months ended		Year ended
Sl. No.	Particulars	31.12.2014 Unaudited	30.09.2014 Unaudited	31.12.2013 Unaudited	31.12.2014 Unaudited	31.12.2013 Unaudited	31.03.2014 Audited
1	Income from Operations						
	(a) Net Sales/Income from operations	230.72	174.40	200.47	620.60	957.34	1,141.69
	(b) Other Operating Income	0.29	-	-	0.29	-	0.42
	Total Income from Operations (net)	231.01	174.40	200.47	620.89	957.34	1,142.11
2	Expenses						
	(a) Cost of materials consumed	162.35	115.10	152.55	442.04	746.90	876.70
	(b) Purchases of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work in progress and stock in trade	6.15	4.19	(8.25)	7.34	1.03	(0.90)
	(d) Employee benefits expenses	14.32	11.31	14.75	36.25	44.05	60.93
	(e) Depreciation and Amortisation expenses	6.58	6.58	6.53	19.74	19.59	26.33
	(f) Other expenses	36.15	29.88	42.44	97.19	136.16	157.77
	Total Expenses	225.55	167.06	208.02	602.56	947.73	1,120.83
3	Profit/(Loss) from operation before other income, finance costs and exceptional items (1-2)	5.46	7.34	(7.55)	18.33	9.61	21.28
4	Other Income	-	-	-	-	-	-
5	Profit/(Loss) from ordinary activities before finance, cost and exceptional items (3+4)	5.46	7.34	(7.55)	18.33	9.61	21.28
6	Finance Costs	-	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance, cost but before exceptional items (5-6)	5.46	7.34	(7.55)	18.33	9.61	21.28
8	Exceptional Items	-	-	-	-	-	-
9	Profit/(Loss) from ordinary activities before Tax (7-8)	5.46	7.34	(7.55)	18.33	9.61	21.28
10	Tax Expense	-	-	-	-	-	12.63
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	5.46	7.34	(7.55)	18.33	9.61	8.65
12	Extraordinary Items (net of tax expense)	-	-	-	-	-	-
13	Net Profit/(Loss) for the period (11+12)	5.46	7.34	(7.55)	18.33	9.61	8.65
14	Share of profit/(Loss) of associates*	-	-	-	-	-	-
15	Minority Interest*	-	-	-	-	-	-
16	Net Profit/(Loss) after taxes, minority and share of profit/(Loss) of associates (13+14+15)	5.46	7.34	(7.55)	18.33	9.61	8.65
17	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	438.90	438.90	438.90	438.90	438.90	438.90
18	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19	Earning Per Share (Basic & Diluted)	1.00	1.00	1.00	1.00	1.00	2.46

Part II

A	PARTICULARS OF SHARE HOLDING						
1	Public Share Holding						
	- No of Shares	33,40,400	32,41,100	31,44,900	33,40,400	31,44,900	32,54,900
	- Percentage of Share holding	76.12%	73.85%	71.65%	76.12%	71.65%	74.17%
2	Promoters and Promoter Group Share Holding						
	(a) Pledged/Encumbered						
	- No. of Shares	-	-	-	-	-	-
	- Percentage of Share (as a % of the total share holding of the promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Share (as a % of the total share capital of the company)	-	-	-	-	-	-
	(b) Non-Encumbered						
	- No. of Shares	10,48,200	11,47,500	12,43,700	10,48,200	12,43,700	11,33,700
	- Percentage of Share (as a % of the total share holding of the promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of Share (as a % of the total share capital of the company)	23.88%	26.15%	28.34%	23.88%	28.34%	25.83%

- The above results were taken on record by the audit committee on 14.02.2015 and by the board of Directors at the meeting held on 14.02.2015 at registred office of the company at Indore
- Previous year figures have been regrouped / rearranged wherever necessary
- Statutory auditor of the company have carried out a limited review of the above result

Yours faithfully
For, KABRA DRUGS LIMITED



DIRECTOR/AUTHORIZED SIGNATORY

Place : Indore
Date: 14 February 2015



REVIEW REPORT FOR THE QUARTER ENDED 31st DECEMBER, 2014

To,
The Board of Directors
Kabra Drugs Limited


We have reviewed the accompanying statement of unaudited financial results of Kabra Drugs Limited for the quarter ended 31st December, 2014. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agrawal Jhavar & Associates
Chartered Accountants
(Firm Reg. No. 008614C)

Dharmendra Agrawal
Partner
M.No. 77507



Place: Indore

Dated: 14th February, 2015